UDC

616.1-02-054(470.111)

Authors

Belova Natalya Igorevna
Northern State Medical University (Arkhangelsk, Russia)
Lavrinov Petr Anatolyevich
Postgraduate Student, Northern State Medical University (Arkhangelsk, Russia)
Vorobyeva Nadezhda Aleksandrovna
Northern State Medical University; Northern Branch of the Hematology Research Centre, Russian Academy of Medical Sciences (Arkhangelsk, Russia)

Abstract

As a result of the Far North development, the lifestyle of the indigenous ethnic group – the Nenets – is changing. Thus, a systematic research is required to identify those who need cardiovascular diseases prevention. Currently, the predictive value of certain markers, such as P-selectin, soluble CD40 ligand (sCD40L), homocysteine, and tissue plasminogen activator (t-PA), is being actively studied. The cardiomarkers analysis of the Nenets population has shown increased homocysteine level, deficiency of folic acid (responsible for its metabolism), fibrinolytic hemostasis inhibition and increased functional platelets activity. Thus, the study of new risk markers for cardiovascular pathology in the Nenets population allows us to talk about serious abnormalities at all levels of hemostasis.

Keywords

the Nenets, homocysteine, P-selectin, CD40L, folic acid, t-PA, cardiovascular diseases

References

1. Barbarash O.L., Osokina A.V. Rol’ markerov sistemy CD40/CD40L v prognoziro-vanii serdechno-sosudistykh sobytiy pri koronarnom ateroskleroze [Role of CD40/Cd40l Markers in Prognosing Cardiovascular Events in Patients with Coronary Atherosclerosis]. Patologiya krovoobrashcheniya i kardiokhirurgiya, 2011, no. 3, pp. 89–93. 
2. Belova N.I., Lavrinov P.A., Vorob’eva N.A., Zueva T.N., Ayvazova E.A. Alimentarnyy status korennogo naseleniya Nenetskogo avtonomnogo okruga [Alimentary Status of Native Population of the Nenets Autonomous Area]. Ekologiya cheloveka, 2013, no. 7, pp. 10–14. 
3. Belova N.I., Lavrinov P.A., Vorob’eva N.A. Faktory riska razvitiya gipergomotsisteinemii v populyatsii korennogo etnosa Nenetskogo avtonomnogo okruga [Risk Factors of Hyperhomocysteinemia Among Indigenous Ethnos in Nenets Autonomous Area]. Tromboz, gemostaz i reologiya, 2014, no. 1 (57), pp. 47–52. 
4. Goldobin V.V., Klocheva E.G., Sirotkina O.V., Vavilova T.V., Laskovets A.B., Bibulatov B.V., Lachinova T.M., Mashkova N.P., Topuzova M.P. Klinicheskie i gemoreologiche-skie narusheniyau patsientov s lakunarnymi insul’tami [Clinical and Hemoreologic Disorders in Patients with Lacunar Stroke]. Vestnik Rossiyskoy voenno-meditsinskoy akademii, 2012, vol. 1, no. 37, pp. 145–148. 
5. Semenov A.V., Panchenko E.P., Ruda M.Ya. Rastvorimyy P-selektin – marker aktivatsii trombotsitov i porazheniya sosudistoy stenki: povyshenie ego urovnya v plazme krovi pri infarkte miokarda, rasprostranennom ateroskleroze i pervichnoy legochnoy gipertonii [Soluble P-selectin as a Marker of Platelet Activation and Destruction of the Vascular Wall: Elevation of Its Level in the Blood Plasma at Myocardial Infarction, Wide-Spread Atherosclerosis and Primary Pulmonary Hypertension]. Terapevticheskiy arkhiv, 2000, vol. 72, no. 4, pp. 15–20. 
6. Sidorov P.I., Degteva G.N., Zubov L.A. Strategii polyarnoy meditsiny [Arctic Medicine Strategies]. Problemy zdravookhraneniya i sotsial’nogo razvitiya Arkticheskoy zony Rossii [Problems of Health and Social Development of the Russian Arctic Zone]. Moscow, 2011, pp. 452–467. 
7. Sirotkina O.V., Bogan’kova N.A., Laskovets A.B., Kukharchik G.A., Gaykovaya L.B., Vavilova T.V. Immunologicheskie metody v otsenke funktsional’noy aktivnosti trombotsitov u bol’nykh s serdechno-sosudistymi zabolevaniyami [Immunological Methods of Evaluating Functional Platelet Activity in Patients with Cardiovascular Diseases]. Meditsinskaya immunologiya, 2010, vol. 12, no. 3, pp. 213–218. 
8. Bhatt D.L., Topol E.J. Scientific and Therapeutic Advances in Antiplatelet Therapy. Nature Reviews Drug Discovery, 2003, vol. 2, pp. 15–28. 
9. Komarov A.L., Shahmatovа O.O., Rebrikov D.V. Prothrombotic Polymorphisms and Long-Term Prognosis of Patients with Stable Ischemic Heart Disease. Ratsional’naya farmakoterapiya v kardiologii, 2011, vol. 7, no. 4, pp. 409–425. 
10. Lonn E., Yusuf S., Arnold M.J., Sheridan P., Pogue J., Micks M., McQueen M.J., Probstfield J., Fodor G., Held C., Genest J. Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. N. Engl. J. Med., 2006, no. 354, pp. 1567–1577. 
11. Saposnik G., Ray J.G., Sheridan P., Mcqueen M., Lonn E. Homocysteine-Lowering Therapy and Stroke Risk, Severity, and Disability: Additional Findings from the HOPE 2 Trial. STROKE, 2009, no. 4, pp. 69–77. 
12. Toole J.F., Malinow M.R., Chambless L.E., Spence J.D., Pettigrew L.C., Howard V.J., Sides E.G., Wang C.H., Stampfer M. Lowering Homocysteine in Patients with Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. JAMA, 2004, no. 291, pp. 565–575. 
13. William P., Nadish G., Madhavi S. Vascular Functions of the Plasminogen Activation System. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, vol. 27, pp. 1231–1237.